Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 69

1.

An optimized retinoic acid-inducible gene I agonist M8 induces immunogenic cell death markers in human cancer cells and dendritic cell activation.

Castiello L, Zevini A, Vulpis E, Muscolini M, Ferrari M, Palermo E, Peruzzi G, Krapp C, Jakobsen M, Olagnier D, Zingoni A, Santoni A, Hiscott J.

Cancer Immunol Immunother. 2019 Sep;68(9):1479-1492. doi: 10.1007/s00262-019-02380-2. Epub 2019 Aug 28.

PMID:
31463653
2.

Interplay of protein corona and immune cells controls blood residency of liposomes.

Giulimondi F, Digiacomo L, Pozzi D, Palchetti S, Vulpis E, Capriotti AL, Chiozzi RZ, Laganà A, Amenitsch H, Masuelli L, Mahmoudi M, Screpanti I, Zingoni A, Caracciolo G.

Nat Commun. 2019 Aug 15;10(1):3686. doi: 10.1038/s41467-019-11642-7.

3.

Activation of liver X receptor up-regulates the expression of the NKG2D ligands MICA and MICB in multiple myeloma through different molecular mechanisms.

Bilotta MT, Abruzzese MP, Molfetta R, Scarno G, Fionda C, Zingoni A, Soriani A, Garofalo T, Petrucci MT, Ricciardi MR, Paolini R, Santoni A, Cippitelli M.

FASEB J. 2019 Aug;33(8):9489-9504. doi: 10.1096/fj.201900319R. Epub 2019 May 24.

PMID:
31125275
4.

Unilateral and Multiple Cavitation Sounds During Lumbosacral Spinal Manipulation.

Mourad F, Dunning J, Zingoni A, Iorio R, Butts R, Zacharko N, Fernández-de-Las-Peñas C.

J Manipulative Physiol Ther. 2019 Jan;42(1):12-22. doi: 10.1016/j.jmpt.2018.08.002. French.

PMID:
31054595
5.

The homeobox transcription factor MEIS2 is a regulator of cancer cell survival and IMiDs activity in Multiple Myeloma: modulation by Bromodomain and Extra-Terminal (BET) protein inhibitors.

Abruzzese MP, Bilotta MT, Fionda C, Zingoni A, Soriani A, Petrucci MT, Ricciardi MR, Molfetta R, Paolini R, Santoni A, Cippitelli M.

Cell Death Dis. 2019 Apr 11;10(4):324. doi: 10.1038/s41419-019-1562-9.

6.

Senescent cells: Living or dying is a matter of NK cells.

Antonangeli F, Zingoni A, Soriani A, Santoni A.

J Leukoc Biol. 2019 Jun;105(6):1275-1283. doi: 10.1002/JLB.MR0718-299R. Epub 2019 Feb 27. Review.

PMID:
30811627
7.

Cancer Exosomes as Conveyors of Stress-Induced Molecules: New Players in the Modulation of NK Cell Response.

Vulpis E, Soriani A, Cerboni C, Santoni A, Zingoni A.

Int J Mol Sci. 2019 Jan 31;20(3). pii: E611. doi: 10.3390/ijms20030611. Review.

8.

Key Role of the CD56lowCD16low Natural Killer Cell Subset in the Recognition and Killing of Multiple Myeloma Cells.

Vulpis E, Stabile H, Soriani A, Fionda C, Petrucci MT, Mariggio' E, Ricciardi MR, Cippitelli M, Gismondi A, Santoni A, Zingoni A.

Cancers (Basel). 2018 Nov 29;10(12). pii: E473. doi: 10.3390/cancers10120473.

9.

Translating the anti-myeloma activity of Natural Killer cells into clinical application.

Fionda C, Stabile H, Molfetta R, Soriani A, Bernardini G, Zingoni A, Gismondi A, Paolini R, Cippitelli M, Santoni A.

Cancer Treat Rev. 2018 Nov;70:255-264. doi: 10.1016/j.ctrv.2018.10.005. Epub 2018 Oct 10. Review.

PMID:
30326421
10.

Exosome-delivered microRNAs promote IFN-α secretion by human plasmacytoid DCs via TLR7.

Salvi V, Gianello V, Busatto S, Bergese P, Andreoli L, D'Oro U, Zingoni A, Tincani A, Sozzani S, Bosisio D.

JCI Insight. 2018 May 17;3(10). pii: 98204. doi: 10.1172/jci.insight.98204. eCollection 2018 May 17.

11.

MICA-129 Dimorphism and Soluble MICA Are Associated With the Progression of Multiple Myeloma.

Zingoni A, Vulpis E, Cecere F, Amendola MG, Fuerst D, Saribekyan T, Achour A, Sandalova T, Nardone I, Peri A, Soriani A, Fionda C, Mariggiò E, Petrucci MT, Ricciardi MR, Mytilineos J, Cippitelli M, Cerboni C, Santoni A.

Front Immunol. 2018 May 1;9:926. doi: 10.3389/fimmu.2018.00926. eCollection 2018.

12.

Drug-Induced Senescent Multiple Myeloma Cells Elicit NK Cell Proliferation by Direct or Exosome-Mediated IL15 Trans-Presentation.

Borrelli C, Ricci B, Vulpis E, Fionda C, Ricciardi MR, Petrucci MT, Masuelli L, Peri A, Cippitelli M, Zingoni A, Santoni A, Soriani A.

Cancer Immunol Res. 2018 Jul;6(7):860-869. doi: 10.1158/2326-6066.CIR-17-0604. Epub 2018 Apr 24.

13.

NKG2D and Its Ligands: "One for All, All for One".

Zingoni A, Molfetta R, Fionda C, Soriani A, Paolini R, Cippitelli M, Cerboni C, Santoni A.

Front Immunol. 2018 Mar 12;9:476. doi: 10.3389/fimmu.2018.00476. eCollection 2018. Review.

14.

Hepatitis C virus direct-acting antivirals therapy impacts on extracellular vesicles microRNAs content and on their immunomodulating properties.

Santangelo L, Bordoni V, Montaldo C, Cimini E, Zingoni A, Battistelli C, D'Offizi G, Capobianchi MR, Santoni A, Tripodi M, Agrati C.

Liver Int. 2018 Oct;38(10):1741-1750. doi: 10.1111/liv.13700. Epub 2018 Feb 24.

PMID:
29359389
15.

Natural Killer Cell Response to Chemotherapy-Stressed Cancer Cells: Role in Tumor Immunosurveillance.

Zingoni A, Fionda C, Borrelli C, Cippitelli M, Santoni A, Soriani A.

Front Immunol. 2017 Sep 25;8:1194. doi: 10.3389/fimmu.2017.01194. eCollection 2017. Review.

16.

CAVITATION SOUNDS DURING CERVICOTHORACIC SPINAL MANIPULATION.

Dunning J, Mourad F, Zingoni A, Iorio R, Perreault T, Zacharko N, de Las Peñas CF, Butts R, Cleland JA.

Int J Sports Phys Ther. 2017 Aug;12(4):642-654.

17.

Genotoxic stress modulates the release of exosomes from multiple myeloma cells capable of activating NK cell cytokine production: Role of HSP70/TLR2/NF-kB axis.

Vulpis E, Cecere F, Molfetta R, Soriani A, Fionda C, Peruzzi G, Caracciolo G, Palchetti S, Masuelli L, Simonelli L, D'Oro U, Abruzzese MP, Petrucci MT, Ricciardi MR, Paolini R, Cippitelli M, Santoni A, Zingoni A.

Oncoimmunology. 2017 Jan 13;6(3):e1279372. doi: 10.1080/2162402X.2017.1279372. eCollection 2017.

18.

High expression levels of IP10/CXCL10 are associated with modulation of the natural killer cell compartment in multiple myeloma.

Bernardini G, Vulpis E, Bonanni V, Stabile H, Ricciardi MR, Petrucci MT, Gismondi A, Santoni A, Zingoni A.

Leuk Lymphoma. 2017 Oct;58(10):2493-2496. doi: 10.1080/10428194.2017.1295144. Epub 2017 Feb 28. No abstract available.

PMID:
28278706
19.

p38 MAPK differentially controls NK activating ligands at transcriptional and post-transcriptional level on multiple myeloma cells.

Soriani A, Borrelli C, Ricci B, Molfetta R, Zingoni A, Fionda C, Carnevale S, Abruzzese MP, Petrucci MT, Ricciardi MR, La Regina G, Di Cesare E, Lavia P, Silvestri R, Paolini R, Cippitelli M, Santoni A.

Oncoimmunology. 2016 Dec 2;6(1):e1264564. doi: 10.1080/2162402X.2016.1264564. eCollection 2017.

20.

Inhibition of bromodomain and extra-terminal (BET) proteins increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: role of cMYC-IRF4-miR-125b interplay.

Abruzzese MP, Bilotta MT, Fionda C, Zingoni A, Soriani A, Vulpis E, Borrelli C, Zitti B, Petrucci MT, Ricciardi MR, Molfetta R, Paolini R, Santoni A, Cippitelli M.

J Hematol Oncol. 2016 Dec 1;9(1):134.

21.

NK cell effector functions in a Chédiak-Higashi patient undergoing cord blood transplantation: Effects of in vitro treatment with IL-2.

Cifaldi L, Pinto RM, Rana I, Caniglia M, Angioni A, Petrocchi S, Cancrini C, Cursi L, Palumbo G, Zingoni A, Gismondi A, Rossi P, Santoni A, Cerboni C.

Immunol Lett. 2016 Dec;180:46-53. doi: 10.1016/j.imlet.2016.10.009. Epub 2016 Nov 2.

PMID:
27816481
22.

Distinct Roles for Human Cytomegalovirus Immediate Early Proteins IE1 and IE2 in the Transcriptional Regulation of MICA and PVR/CD155 Expression.

Pignoloni B, Fionda C, Dell'Oste V, Luganini A, Cippitelli M, Zingoni A, Landolfo S, Gribaudo G, Santoni A, Cerboni C.

J Immunol. 2016 Nov 15;197(10):4066-4078. Epub 2016 Oct 12.

23.

Targeting NKG2D and NKp30 Ligands Shedding to Improve NK Cell-Based Immunotherapy.

Zingoni A, Vulpis E, Nardone I, Soriani A, Fionda C, Cippitelli M, Santoni A.

Crit Rev Immunol. 2016;36(6):445-460. doi: 10.1615/CritRevImmunol.2017020166.

PMID:
28845754
24.

Multiple Myeloma Impairs Bone Marrow Localization of Effector Natural Killer Cells by Altering the Chemokine Microenvironment.

Ponzetta A, Benigni G, Antonangeli F, Sciumè G, Sanseviero E, Zingoni A, Ricciardi MR, Petrucci MT, Santoni A, Bernardini G.

Cancer Res. 2015 Nov 15;75(22):4766-77. doi: 10.1158/0008-5472.CAN-15-1320. Epub 2015 Oct 5.

25.

The IMiDs targets IKZF-1/3 and IRF4 as novel negative regulators of NK cell-activating ligands expression in multiple myeloma.

Fionda C, Abruzzese MP, Zingoni A, Cecere F, Vulpis E, Peruzzi G, Soriani A, Molfetta R, Paolini R, Ricciardi MR, Petrucci MT, Santoni A, Cippitelli M.

Oncotarget. 2015 Sep 15;6(27):23609-30.

26.

NKG2D and DNAM-1 Ligands: Molecular Targets for NK Cell-Mediated Immunotherapeutic Intervention in Multiple Myeloma.

Fionda C, Soriani A, Zingoni A, Santoni A, Cippitelli M.

Biomed Res Int. 2015;2015:178698. doi: 10.1155/2015/178698. Epub 2015 Jun 16. Review.

27.

Genotoxic Stress Induces Senescence-Associated ADAM10-Dependent Release of NKG2D MIC Ligands in Multiple Myeloma Cells.

Zingoni A, Cecere F, Vulpis E, Fionda C, Molfetta R, Soriani A, Petrucci MT, Ricciardi MR, Fuerst D, Amendola MG, Mytilineos J, Cerboni C, Paolini R, Cippitelli M, Santoni A.

J Immunol. 2015 Jul 15;195(2):736-48. doi: 10.4049/jimmunol.1402643. Epub 2015 Jun 12.

28.

Tumor-associated and immunochemotherapy-dependent long-term alterations of the peripheral blood NK cell compartment in DLBCL patients.

Cox MC, Battella S, La Scaleia R, Pelliccia S, Di Napoli A, Porzia A, Cecere F, Alma E, Zingoni A, Mainiero F, Ruco L, Monarca B, Santoni A, Palmieri G.

Oncoimmunology. 2015 Jan 7;4(3):e990773. eCollection 2015 Mar.

29.

Nitric oxide donors increase PVR/CD155 DNAM-1 ligand expression in multiple myeloma cells: role of DNA damage response activation.

Fionda C, Abruzzese MP, Zingoni A, Soriani A, Ricci B, Molfetta R, Paolini R, Santoni A, Cippitelli M.

BMC Cancer. 2015 Jan 22;15:17. doi: 10.1186/s12885-015-1023-5.

30.

c-Cbl regulates MICA- but not ULBP2-induced NKG2D down-modulation in human NK cells.

Molfetta R, Quatrini L, Capuano C, Gasparrini F, Zitti B, Zingoni A, Galandrini R, Santoni A, Paolini R.

Eur J Immunol. 2014 Sep;44(9):2761-70. doi: 10.1002/eji.201444512. Epub 2014 Jun 17.

31.

2013 European guideline on the management of lymphogranuloma venereum.

de Vries HJ, Zingoni A, Kreuter A, Moi H, White JA; European Branch of the International Union against Sexually Transmitted Infections; European Academy of Dermatology and Venereology; European Dermatology Forum; European Society of Clinical Microbiology and Infectious Diseases; Union of European Medical Specialists; European Centre for Disease Prevention and Control; European Office of the World Health Organisation.

J Eur Acad Dermatol Venereol. 2015 Jan;29(1):1-6. doi: 10.1111/jdv.12461. Epub 2014 Mar 24.

PMID:
24661352
32.

The DNA Damage Response: A Common Pathway in the Regulation of NKG2D and DNAM-1 Ligand Expression in Normal, Infected, and Cancer Cells.

Cerboni C, Fionda C, Soriani A, Zingoni A, Doria M, Cippitelli M, Santoni A.

Front Immunol. 2014 Jan 7;4:508. doi: 10.3389/fimmu.2013.00508. eCollection 2014 Jan 7. Review.

33.

Group-theoretic insights on the vibration of symmetric structures in engineering.

Zingoni A.

Philos Trans A Math Phys Eng Sci. 2013 Dec 30;372(2008):20120037. doi: 10.1098/rsta.2012.0037. Print 2014 Feb 13.

34.

2013 European Guideline on the management of proctitis, proctocolitis and enteritis caused by sexually transmissible pathogens.

de Vries HJ, Zingoni A, White JA, Ross JD, Kreuter A.

Int J STD AIDS. 2014 Jun;25(7):465-74. doi: 10.1177/0956462413516100. Epub 2013 Dec 18.

PMID:
24352129
35.

Inhibition of glycogen synthase kinase-3 increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: role of STAT3.

Fionda C, Malgarini G, Soriani A, Zingoni A, Cecere F, Iannitto ML, Ricciardi MR, Federico V, Petrucci MT, Santoni A, Cippitelli M.

J Immunol. 2013 Jun 15;190(12):6662-72. doi: 10.4049/jimmunol.1201426. Epub 2013 May 17.

36.

NKG2D and DNAM-1 activating receptors and their ligands in NK-T cell interactions: role in the NK cell-mediated negative regulation of T cell responses.

Zingoni A, Ardolino M, Santoni A, Cerboni C.

Front Immunol. 2013 Jan 9;3:408. doi: 10.3389/fimmu.2012.00408. eCollection 2012.

37.

Human leukocyte antigen E contributes to protect tumor cells from lysis by natural killer cells.

Lo Monaco E, Tremante E, Cerboni C, Melucci E, Sibilio L, Zingoni A, Nicotra MR, Natali PG, Giacomini P.

Neoplasia. 2011 Sep;13(9):822-30.

38.

DNAM-1 ligand expression on Ag-stimulated T lymphocytes is mediated by ROS-dependent activation of DNA-damage response: relevance for NK-T cell interaction.

Ardolino M, Zingoni A, Cerboni C, Cecere F, Soriani A, Iannitto ML, Santoni A.

Blood. 2011 May 5;117(18):4778-86. doi: 10.1182/blood-2010-08-300954. Epub 2011 Mar 15.

PMID:
21406724
39.

Effectiveness of extracorporeal photochemotherapy in the treatment of a case of refractory erosive lichen planus.

Zingoni A, Deboli T, Savoia P, Bernengo MG.

J Dermatolog Treat. 2010 Mar;21(2):119-21. doi: 10.1080/09546630902991468.

40.

Detuning CD8+ T lymphocytes by down-regulation of the activating receptor NKG2D: role of NKG2D ligands released by activated T cells.

Cerboni C, Ardolino M, Santoni A, Zingoni A.

Blood. 2009 Mar 26;113(13):2955-64. doi: 10.1182/blood-2008-06-165944. Epub 2009 Jan 5.

PMID:
19124832
41.

ATM-ATR-dependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-cell susceptibility and is associated with a senescent phenotype.

Soriani A, Zingoni A, Cerboni C, Iannitto ML, Ricciardi MR, Di Gialleonardo V, Cippitelli M, Fionda C, Petrucci MT, Guarini A, Foà R, Santoni A.

Blood. 2009 Apr 9;113(15):3503-11. doi: 10.1182/blood-2008-08-173914. Epub 2008 Dec 19.

PMID:
19098271
42.

Natural killer (NK) cells from killers to regulators: distinct features between peripheral blood and decidual NK cells.

Santoni A, Zingoni A, Cerboni C, Gismondi A.

Am J Reprod Immunol. 2007 Sep;58(3):280-8. Review.

PMID:
17681044
43.

Antigen-activated human T lymphocytes express cell-surface NKG2D ligands via an ATM/ATR-dependent mechanism and become susceptible to autologous NK- cell lysis.

Cerboni C, Zingoni A, Cippitelli M, Piccoli M, Frati L, Santoni A.

Blood. 2007 Jul 15;110(2):606-15. Epub 2007 Apr 3.

PMID:
17405908
44.

Human immunodeficiency virus 1 Nef protein downmodulates the ligands of the activating receptor NKG2D and inhibits natural killer cell-mediated cytotoxicity.

Cerboni C, Neri F, Casartelli N, Zingoni A, Cosman D, Rossi P, Santoni A, Doria M.

J Gen Virol. 2007 Jan;88(Pt 1):242-50.

PMID:
17170457
45.

High-efficient lentiviral vector-mediated gene transfer into primary human NK cells.

Micucci F, Zingoni A, Piccoli M, Frati L, Santoni A, Galandrini R.

Exp Hematol. 2006 Oct;34(10):1344-52.

PMID:
16982327
46.

Recognition of a carbohydrate xenoepitope by human NKRP1A (CD161).

Christiansen D, Mouhtouris E, Milland J, Zingoni A, Santoni A, Sandrin MS.

Xenotransplantation. 2006 Sep;13(5):440-6.

PMID:
16925668
47.

Engagement of NKG2D by cognate ligand or antibody alone is insufficient to mediate costimulation of human and mouse CD8+ T cells.

Ehrlich LI, Ogasawara K, Hamerman JA, Takaki R, Zingoni A, Allison JP, Lanier LL.

J Immunol. 2005 Feb 15;174(4):1922-31.

48.

NK cell regulation of T cell-mediated responses.

Zingoni A, Sornasse T, Cocks BG, Tanaka Y, Santoni A, Lanier LL.

Mol Immunol. 2005 Feb;42(4):451-4. Review.

PMID:
15607797
49.

Cross-talk between activated human NK cells and CD4+ T cells via OX40-OX40 ligand interactions.

Zingoni A, Sornasse T, Cocks BG, Tanaka Y, Santoni A, Lanier LL.

J Immunol. 2004 Sep 15;173(6):3716-24.

50.

Src-dependent Syk activation controls CD69-mediated signaling and function on human NK cells.

Pisegna S, Zingoni A, Pirozzi G, Cinque B, Cifone MG, Morrone S, Piccoli M, Frati L, Palmieri G, Santoni A.

J Immunol. 2002 Jul 1;169(1):68-74.

Supplemental Content

Loading ...
Support Center